Insmed Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INSM research report →
About the company
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils.
- CEO
- William H. Lewis
- IPO
- 2000
- Employees
- 1,271
- HQ
- Bridgewater, NJ, US
Price Chart
- Market Cap
- $24.19B
- P/E
- -19.41
- P/S
- 29.52
- P/B
- 34.12
- EV/EBITDA
- -22.53
- Div Yield
- 0.00%
- Gross Margin
- 81.56%
- Op Margin
- -137.74%
- Net Margin
- -144.44%
- ROE
- -130.11%
- ROIC
- -65.28%
- Revenue
- $606.42M · 66.73%
- Net Income
- $-1,276,775,000 · -39.73%
- EPS
- $-6.41 · -15.08%
- Op Income
- $-1,176,729,000
- FCF YoY
- -37.09%
- 52W High
- $212.75
- 52W Low
- $90.39
- 50D MA
- $111.50
- 200D MA
- $151.76
- Beta
- 0.77
- Avg Volume
- 3.73M
Get TickerSpark's AI analysis on INSM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Lewis William | other | 8,880 |
| Jun 25, 26 | Lewis William | other | 12,518 |
| Jun 25, 26 | Lewis William | sell | 12,091 |
| Jun 25, 26 | Lewis William | sell | 1,836 |
| Jun 25, 26 | Lewis William | sell | 3,723 |
| Jun 25, 26 | Lewis William | sell | 2,456 |
| Jun 25, 26 | Lewis William | sell | 1,292 |
| Jun 25, 26 | Lewis William | other | 12,518 |
| Jun 25, 26 | Lewis William | other | 8,880 |
| Jun 23, 26 | Butera Samuele | other | 12,570 |
Our INSM coverage
Recent articles, reports, and earnings notes.
Insmed (INSM): BRINSUPRI Launch Drives Premium Growth
Insmed has evolved into a commercial-stage rare respiratory company with two marketed products and a fast-scaling launch. BRINSUPRI is driving the revenue inflection, while ARIKAYCE and a late-stage pipeline add durability and upside.
Insmed Incorporated (INSM) climbs 10.8% on growth outlook
Insmed Incorporated (INSM) climbs sharply as investors continue to digest its strong Q1 update, including rapid BRINSUPRI growth, steady ARIKAYCE sales, and encouraging ENCORE data. The move reflects renewed confidence in the company’s 2026 revenue targets and its expanding commercial and pipeline story.
Want a deeper read on INSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.